Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients

Journal of Diabetes and its Complications

Volumn 26, Issue 4, 2012, Pages 308-312

  Lee, Jun Ho ^a   Kim, Sang Soo ^b   Kim, In Joo ^b   Song, Sang Heon ^b   Kim, Yong Ki ^c   In Kim, Ju ^b   Jeon, Yun Kyung ^b   Kim, Bo Hyun ^b   Kwak, Ihm Soo ^b  

^a Department of Internal Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c Kim Yong Ki Internal Medicine Clinic   (South Korea)

Author keywords

Albuminuria; Diabetic nephropathy; Inflammation; Type 2 diabetes mellitus; YKL 40

Indexed keywords

BIOLOGICAL MARKER; CARTILAGE GLYCOPROTEIN 39; GLYCOPROTEIN GP 39; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; UNIVARIATE ANALYSIS;

ADIPOKINES; ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; LECTINS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84863775398     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.04.012     Document Type: Article

References (23)

1. Brix, J. M., Hollerl, F., Koppensteiner, R., Schernthaner, G., & Schernthaner, G. H. (2011). YKL-40 in type 2 diabetic patients with different levels of albuminuria. European Journal of Clinical Investigation, 41, 589-596.
2. Cooper, M. E. (2001). Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia, 44, 1957-1972.
3. Hakala, B. E., White, C., & Recklies, A. D. (1993). Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. The Journal of Biological Chemistry, 268, 25803-25810. (Pubitemid 23358198)
4. Jager, A., van Hinsbergh, V. W., Kostense, P. J., Emeis, J. J., Nijpels, G., Dekker, J. M., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. (2002). C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 593-598. (Pubitemid 34408739)
5. Jialal, I., Devaraj, S., & Venugopal, S. K. (2004). C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44, 6-11. (Pubitemid 38823477)
6. Kim, N. H., Oh, J. H., Seo, J. A., Lee, K. W., Kim, S. G., Choi, K. M., Baik, S. H., Choi, D. S., Kang, Y. S., Han, S. Y., Han, K. H., Ji, Y. H., & Cha, D. R. (2005). Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney International, 67, 167-177. (Pubitemid 40019238)
7. Kucur, M., Isman, F. K., Karadag, B., Vural, V. A., & Tavsanoglu, S. (2007). Serum YKL-40 levels in patients with coronary artery disease. Coronary Artery Disease, 18, 391-396. (Pubitemid 47186840)
8. Malinda, K. M., Ponce, L., Kleinman, H. K., Shackelton, L. M., & Millis, A. J. (1999). Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Experimental Cell Research, 250, 168-173. (Pubitemid 29391580)
9. Matheson, A., Willcox, M. D., Flanagan, J., & Walsh, B. J. (2010). Urinary biomarkers involved in type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews, 26, 150-171.
10. Myers, G. L., Miller,W. G., Coresh, J., Fleming, J., Greenberg, N., Greene, T., Hostetter, T., Levey, A. S., Panteghini, M., Welch, M., & Eckfeldt, J. H. (2006). Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry, 52, 5-18. (Pubitemid 43032461)
11. Narita, T., Sasaki, H., Hosoba, M., Miura, T., Yoshioka, N., Morii, T., Shimotomai, T., Koshimura, J., Fujita, H., Kakei, M., & Ito, S. (2004). Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care, 27, 1176-1181. (Pubitemid 38579786)
12. Navarro, J. F., Mora, C., Muros, M., & Garcia, J. (2006). Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrology, Dialysis, Transplantation, 21, 3428-3434. (Pubitemid 44817091)
13. Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de Fuentes, M., & Garcia-Perez, J. (2011). Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Reviews Nephrology, 7, 327-340.
14. Nielsen, A. R., Erikstrup, C., Johansen, J. S., Fischer, C. P., Plomgaard, P., Krogh-Madsen, R., Taudorf, S., Lindegaard, B., & Pedersen, B. K. (2008). Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes, 57, 3078-3082.
15. Nordenbaek, C., Johansen, J. S., Junker, P., Borregaard, N., Sorensen, O., & Price, P. A. (1999). YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. The Journal of Infectious Diseases, 180, 1722-1726. (Pubitemid 29506483)
16. Ostergaard, C., Johansen, J. S., Benfield, T., Price, P. A., & Lundgren, J. D. (2002). YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clinical and Diagnostic Laboratory Immunology, 9, 598-604. (Pubitemid 34538220)
17. Rathcke, C. N., Johansen, J. S., & Vestergaard, H. (2006). YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammation Research, 55, 53-59.
18. Rathcke, C. N., & Vestergaard, H. (2006). YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflammation Research, 55, 221-227. (Pubitemid 44359135)
19. Rathcke, C. N., Persson, F., Tarnow, L., Rossing, P., & Vestergaard, H. (2009). YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patientswith type 1 diabetes and increases with levels of albuminuria. Diabetes Care, 32, 323-328.
20. Rathcke, C. N., Raymond, I., Kistorp, C., Hildebrandt, P., Faber, J., & Vestergaard, H. (2010). Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. International Journal of Cardiology, 143, 35-42.
21. Rondbjerg, A. K., Omerovic, E., & Vestergaard, H. (2011). YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovascular Diabetology, 10, 54.
22. Wang, Q. Y., & Chen, F. Q. (2009). Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 83, 215-219.
23. Zheng, J. L., Lu, L., Hu, J., Zhang, R. Y., Zhang, Q., Chen, Q. J., & Shen, W. F. (2010). Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis, 210, 590-595.